Does VEDOLIZUMAB Cause Hepatic lesion? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Hepatic lesion have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 0.0% of all adverse event reports for VEDOLIZUMAB.
16
Reports of Hepatic lesion with VEDOLIZUMAB
0.0%
of all VEDOLIZUMAB reports
0
Deaths
11
Hospitalizations
How Dangerous Is Hepatic lesion From VEDOLIZUMAB?
Of the 16 reports, 11 (68.8%) required hospitalization.
Is Hepatic lesion Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VEDOLIZUMAB. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does VEDOLIZUMAB Cause?
Off label use (21,017)
Colitis ulcerative (13,455)
Crohn's disease (9,759)
Drug ineffective (8,424)
Diarrhoea (7,493)
Abdominal pain (6,401)
Fatigue (5,477)
Haematochezia (5,215)
Frequent bowel movements (4,527)
Arthralgia (4,028)
What Other Drugs Cause Hepatic lesion?
OCTREOTIDE (296)
EVEROLIMUS (171)
RIBOCICLIB (144)
LETROZOLE (139)
CAPECITABINE (124)
ADALIMUMAB (123)
METHOTREXATE (108)
FULVESTRANT (107)
PALBOCICLIB (104)
CYCLOPHOSPHAMIDE (101)
Which VEDOLIZUMAB Alternatives Have Lower Hepatic lesion Risk?
VEDOLIZUMAB vs VELAGLUCERASE ALFA
VEDOLIZUMAB vs VELCADE
VEDOLIZUMAB vs VELETRI
VEDOLIZUMAB vs VELIPARIB
VEDOLIZUMAB vs VEMURAFENIB